MRK

Merck & Co
D

MRK

Arincen67/100B

Merck & Co return on equity (ROE)

Merck & Co's return on equity is 5.46%: net income of 2.45B USD over the last twelve months on shareholders' equity of 44.89B USD.

Today
5.46%
Average, 5 years
24.60%
Low, 5 years
0.97%
High, 5 years
38.51%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 2.45B ÷ 44.89B = 5.46%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Merck & Co's return on equity so high?

Net margin
28.1%
profit on each dollar of sales
Asset turnover
0.47×
sales on each dollar of assets
Equity multiplier
2.60×
assets on each dollar of equity
Return on equity
34.7%
FY2025
  • FY202528.1% × 0.47 × 2.60 = 34.7%
  • FY202426.7% × 0.55 × 2.53 = 37.0%
  • FY20230.6% × 0.56 × 2.84 = 1.0%
  • FY202224.5% × 0.54 × 2.37 = 31.6%
  • FY202126.8% × 0.46 × 2.77 = 34.2%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today5.46%2.45B44.89B
FY202531 Dec 202534.70%18.25B52.61B
FY202431 Dec 202436.99%17.13B46.31B
FY202331 Dec 20230.97%365.00M37.58B
FY202231 Dec 202231.58%14.53B45.99B
FY202131 Dec 202132.36%12.36B38.18B
FY202031 Dec 202027.97%7.08B25.32B
FY201931 Dec 201937.74%9.78B25.91B
FY201831 Dec 201823.19%6.19B26.70B
FY201731 Dec 20177.04%2.42B34.34B
FY201631 Dec 20169.83%3.94B40.09B
FY201531 Dec 20159.98%4.46B44.68B
FY201431 Dec 201424.53%11.93B48.65B
FY201331 Dec 20139.08%4.52B49.77B
FY201231 Dec 201211.88%6.30B53.02B
FY201131 Dec 201111.72%6.39B54.52B
FY201031 Dec 20101.81%982.00M54.38B
FY200931 Dec 200922.05%13.02B59.06B
FY200831 Dec 200841.63%7.81B18.76B
FY200731 Dec 200718.01%3.28B18.18B
FY200631 Dec 200625.25%4.43B17.56B
FY200531 Dec 200525.76%4.63B17.98B
FY200431 Dec 200433.63%5.81B17.29B
FY200331 Dec 200343.85%6.83B15.58B
FY200231 Dec 200239.28%7.15B18.20B
FY200131 Dec 200145.37%7.28B16.05B
FY200031 Dec 200045.99%6.82B14.83B
FY199931 Dec 199944.48%5.89B13.24B
FY199831 Dec 199841.00%5.25B12.80B
FY199731 Dec 199736.64%4.61B12.59B
FY199631 Dec 199632.42%3.88B11.97B
FY199531 Dec 199528.42%3.34B11.74B
FY199431 Dec 199426.91%3.00B11.14B
FY199331 Dec 199321.62%2.17B10.02B
FY199231 Dec 199248.90%2.45B5.00B
FY199131 Dec 199143.16%2.12B4.92B
FY199031 Dec 199046.45%1.78B3.83B
FY198931 Dec 198942.48%1.50B3.52B
FY198831 Dec 198842.26%1.21B2.86B
FY198731 Dec 198742.82%906.40M2.12B
FY198631 Dec 198626.30%675.70M2.57B
FY198531 Dec 198520.50%539.90M2.63B

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Merck & Co's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.